Provided by Tiger Trade Technology Pte. Ltd.

Cogent

25.41
+1.124.61%
Volume:274.04K
Turnover:6.80M
Market Cap:1.25B
PE:-6.25
High:25.66
Open:24.30
Low:23.62
Close:24.29
52wk High:84.06
52wk Low:15.96
Shares:49.12M
Float Shares:47.97M
Volume Ratio:0.52
T/O Rate:0.57%
Dividend:3.05
Dividend Rate:12.00%
EPS(TTM):-4.0643
EPS(LYR):-4.2848
ROE:-136.94%
ROA:-2.47%
PB:-31.87
PE(LYR):-5.93

Loading ...

Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026

GlobeNewswire
·
Feb 02

Cogent Communications Holdings Inc. to Host Earnings Call and Release Operating Results

Reuters
·
Jan 29

Cogent Biosciences: Breakthrough Bezuclastinib Data, Expanding SM Franchise, and Emerging Pipeline Support Raised $54 Buy Target

TIPRANKS
·
Jan 27

Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)

GlobeNewswire
·
Jan 26

Cogent Biosciences Expands HER2 Oncology Footprint With New Early-Stage CGT4255 Trial

TIPRANKS
·
Jan 24

Cogent Biosciences Price Target Maintained With a $55.00/Share by Wedbush

Dow Jones
·
Jan 21

Cogent price target lowered to $21 from $25 at BofA

TIPRANKS
·
Jan 21

Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)

GlobeNewswire
·
Jan 20

Assessing Cogent Communications Holdings (CCOI) Valuation After Dividend Cut And Securities Investigation

Simply Wall St.
·
Jan 18

Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio

GlobeNewswire
·
Jan 12

Cogent Communications Extends CEO Contract With New Pay Terms and Equity Awards

Reuters
·
Jan 08

Cogent Biosciences Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jan 06

Cogent Biosciences Chief Scientific Officer John Robinson Sells 50% Of Holding

Simply Wall St.
·
Jan 02

Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis

GlobeNewswire
·
Dec 30, 2025

Is Dividend Slashing And Legal Scrutiny Altering The Investment Case For Cogent Communications (CCOI)?

Simply Wall St.
·
Dec 24, 2025

Cogent Biosciences Is Maintained at Overweight by JP Morgan

Dow Jones
·
Dec 20, 2025

Assessing Cogent Communications Holdings (CCOI) Valuation After Ongoing Insider Share Sales by Its CFO

Simply Wall St.
·
Dec 15, 2025

Cogent Communications CFO Thaddeus Gerard Weed Reports Sale of Common Shares

Reuters
·
Dec 13, 2025

Does Cogent Communications (CCOI) Buyback Resumption and Insider Selling Reveal a Deeper Capital Allocation Shift?

Simply Wall St.
·
Dec 09, 2025

Cogent Communications VP of Network Strategy Henry W. Kilmer Reports Sale of Common Shares

Reuters
·
Dec 09, 2025